JP2016538318A5 - - Google Patents

Info

Publication number

JP2016538318A5

JP2016538318A5 JP2016537831A JP2016537831A JP2016538318A5 JP 2016538318 A5 JP2016538318 A5 JP 2016538318A5 JP 2016537831 A JP2016537831 A JP 2016537831A JP 2016537831 A JP2016537831 A JP 2016537831A JP 2016538318 A5 JP2016538318 A5 JP 2016538318A5

Authority

JP

Japan

Prior art keywords

seq

residues

antibody

cdr

sez6

Prior art date

2014-08-27

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 108090001123 antibodies Proteins 0.000 claims 66
• 102000004965 antibodies Human genes 0.000 claims 66
• 239000008194 pharmaceutical composition Substances 0.000 claims 16
• 239000002254 cytotoxic agent Substances 0.000 claims 15
• 231100000599 cytotoxic agent Toxicity 0.000 claims 15
• 102100017801 SEZ6 Human genes 0.000 claims 12
• 108060007423 SEZ6 Proteins 0.000 claims 12
• 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims 12
• 206010041067 Small cell lung cancer Diseases 0.000 claims 12
• 239000000611 antibody drug conjugate Substances 0.000 claims 9
• 108091008116 antibody drug conjugates Proteins 0.000 claims 9
• 239000003814 drug Substances 0.000 claims 9
• HXCHCVDVKSCDHU-LULTVBGHSA-N Calicheamicin Chemical group C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 6
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
• 229940079593 drugs Drugs 0.000 claims 6
• 208000009018 medullary Thyroid cancer Diseases 0.000 claims 6
• 108010045030 monoclonal antibodies Proteins 0.000 claims 6
• 102000005614 monoclonal antibodies Human genes 0.000 claims 6
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 6
• NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 3
• CIORWBWIBBPXCG-JZTFPUPKSA-N Amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2CC(O)C[C@H]2C(=O)N[C@@H](C(C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H](C(C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-JZTFPUPKSA-N 0.000 claims 3
• VQNATVDKACXKTF-XELLLNAOSA-N Duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims 3
• 230000035693 Fab Effects 0.000 claims 3
• 150000001413 amino acids Chemical class 0.000 claims 3
• 239000000427 antigen Substances 0.000 claims 3
• 102000038129 antigens Human genes 0.000 claims 3
• 108091007172 antigens Proteins 0.000 claims 3
• 108010044540 auristatin Proteins 0.000 claims 3
• 238000002512 chemotherapy Methods 0.000 claims 3
• 108091006028 chimera Proteins 0.000 claims 3
• 238000004519 manufacturing process Methods 0.000 claims 3
• 230000035772 mutation Effects 0.000 claims 3
• 229910052697 platinum Inorganic materials 0.000 claims 3
• YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical compound C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims 3
• 239000000562 conjugate Substances 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 238000002372 labelling Methods 0.000 claims 1